Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of...

Related Keywords

Montreal ,Quebec ,Canada ,Chicago ,Illinois ,United States ,American ,Philippe Dubuc ,Julie Schneiderman ,Ira Winer ,Theratechnologie Sudocetaxel Zendusortide ,Christian Marsolais ,Linkedin ,American Society Of Clinical Oncology ,Professor Of Oncology At Wayne State University ,Theratechnologies Inc ,Communications Corporate Affairs ,Twitter ,Demonstrates Signs ,Long Term Efficacy ,Manageable Safety Profile ,Clinical Oncology ,Response Evaluation Criteria ,Solid Tumors ,Gynecologic Oncology ,Trials Multidisciplinary Teams ,Karmanos Cancer Center ,Associate Professor ,Wayne State ,Senior Vice President ,Chief Medical Officer ,Sudocetaxel Zendusortide ,Fast Track ,Forward Looking Statements ,Looking Statements ,Vice President ,Chief Financial ,